InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $15.900 0.16 (1.02%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,404 ZIRCON Data Presented at AUA Confirms Efficacy in 2cm Masses 1 May 2023 8:14AM $10.150 $15.900 risen by 56.65%
$5,404 Proposed issue of securities - TLX 27 Apr 2023 8:15AM $10.390 $15.900 risen by 53.03%
$5,404 Presentation to Accompany AI Development Program Update 27 Apr 2023 8:12AM $10.390 $15.900 risen by 53.03%
$5,404 Telix Accelerates AI Development with Dedicaid Acquisition 27 Apr 2023 8:12AM $10.390 $15.900 risen by 53.03%
$5,404 AGM Notice of Meeting, Proxy Form and Online Guide 21 Apr 2023 8:18AM $9.790 $15.900 risen by 62.41%
$5,404 Q1 2023 Business update to accompany quarterly results 17 Apr 2023 3:53PM $7.830 $15.900 risen by 103.07%
$5,404 Appendix 4C and Activities Report - March 2023 Quarter 17 Apr 2023 3:51PM $7.830 $15.900 risen by 103.07%
$5,404 Telix-Grand Pharma Investor Webcast Notification 17 Apr 2023 8:23AM $7.645 $15.900 risen by 107.98%
$5,404 Telix Preclinical Development of Radiolabelled Olaratumab 17 Apr 2023 8:23AM $7.645 $15.900 risen by 107.98%
$5,404 Notification of upcoming quarterly results and investor call 5 Apr 2023 8:16AM $7.090 $15.900 risen by 124.26%
$5,404 Notification of cessation of securities - TLX 5 Apr 2023 8:16AM $7.090 $15.900 risen by 124.26%
$5,404 Cleansing Notice 5 Apr 2023 8:16AM $7.090 $15.900 risen by 124.26%
$5,404 Application for quotation of securities - TLX 5 Apr 2023 8:14AM $7.090 $15.900 risen by 124.26%
$5,404 Illuccix European Marketing Authorisation Application Update 3 Apr 2023 8:27AM $6.900 $15.900 risen by 130.43%
$5,404 Non-Executive Director Leave of Absence 29 Mar 2023 8:22AM $6.810 $15.900 risen by 133.48%
$5,404 Cleansing Notice 21 Mar 2023 8:20AM $7.070 $15.900 risen by 124.89%
$5,404 Application for quotation of securities - TLX 21 Mar 2023 8:18AM $7.070 $15.900 risen by 124.89%
$5,404 App 3Y Change in Director Interests - T Olson 17 Mar 2023 9:46AM $6.860 $15.900 risen by 131.78%
$5,404 FDA approval of expanded indication of Illuccix in the US 16 Mar 2023 10:36AM $6.590 $15.900 risen by 141.27%
$5,404 Date of 2022 AGM 6 Mar 2023 8:17AM $7.010 $15.900 risen by 126.82%
$5,404 Corporate governance statement - Appendix 4G 27 Feb 2023 4:11PM $6.570 $15.900 risen by 142.01%
$5,404 2022 Full Year Results Presentation 27 Feb 2023 4:11PM $6.570 $15.900 risen by 142.01%
$5,404 2022 Full Year Results Release 27 Feb 2023 4:09PM $6.570 $15.900 risen by 142.01%
$5,404 Appendix 4E and 2022 Annual Report 27 Feb 2023 4:08PM $6.570 $15.900 risen by 142.01%
$5,404 Cleansing Notice 23 Feb 2023 8:18AM $6.290 $15.900 risen by 152.78%

426 - 450 of 961 results

Page 18 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.